Charles River Laboratories International, Inc.

CRL · NYSE · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net — – — 1 disclosure · 1 bought / 0 sold · last Mar 25, 2026
Thomas MacArthur R · HOUSE · NJ	$4K – $60K $11K – $161K today 4 filings · last Sep 19, 2018
Robert Bresnahan R · HOUSE · PA	$1 – $49K $5K – $137K today 2 filings · last May 15, 2025
Julie Johnson D · HOUSE · TX	$1K – $15K $2K – $30K today 1 filing · last Jan 15, 2025
Ro Khanna D · HOUSE · CA	−$97K – $113K −$228K – $222K today 15 filings · last May 15, 2026
Jefferson Shreve R · HOUSE · IN	−$35K – $35K −$84K – $86K today 2 filings · last May 12, 2025
Lois Frankel D · HOUSE · FL	−$14K – $14K −$24K – $26K today 2 filings · last Sep 8, 2023
Zoe Lofgren D · HOUSE · CA	−$14K – $14K −$23K – $11K today 2 filings · last Aug 25, 2022
Lamar Smith R · HOUSE · TX	−$29K – $13K −$78K – $43K today 3 filings · last Sep 26, 2018
Susie Lee D · HOUSE · NV	−$29K – $13K −$77K – $34K today 3 filings · last Oct 8, 2019

Recent transactions

Trades from Feb 13, 2018 – May 15, 2026

Politician	Type	Filed after	Amount
Ro Khanna D · HOUSE · CA-17	Buy	25 days May 15, 2026 → Jun 9, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	49 days Mar 25, 2026 → May 13, 2026	≥$15K
Ro Khanna D · HOUSE · CA-17	Buy	8 days Mar 30, 2026 → Apr 7, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	32 days Feb 5, 2026 → Mar 9, 2026	≥$1K
Jefferson Shreve R · HOUSE · IN-6	Sell	41 days May 12, 2025 → Jun 22, 2025	≥$15K
Jefferson Shreve R · HOUSE · IN-6	Buy	45 days May 8, 2025 → Jun 22, 2025	≥$15K
Robert Bresnahan R · HOUSE · PA-8	Sell	16 days May 15, 2025 → May 31, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	27 days Apr 15, 2025 → May 12, 2025	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	33 days Apr 9, 2025 → May 12, 2025	≥$1K
Robert Bresnahan R · HOUSE · PA-8	Buy	30 days Apr 8, 2025 → May 8, 2025	≥$15K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

584

13F shares

57.3M

Total invested

$13.0B

Ownership

118.2%

New positions

Closed positions

Increased positions

273

Reduced positions

204

Put/Call ratio

0.55

Holder	Reported	Shares	Value	Δ Qtr
FMR LLC	8/13/2026	4.2M	$961.5M	+22.67%
BLACKROCK, INC.	8/7/2026	3.8M	$861.5M	−1.57%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	3.1M	$714.2M	−1.65%
INVESCO LTD.	8/14/2026	3M	$676.9M	+24.51%
HARRIS ASSOCIATES L P	8/14/2026	2.2M	$508.3M	+4.08%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	2.2M	$501.4M	−3.65%
ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC	8/13/2026	1.9M	$436.5M	−4.42%
STATE STREET CORP	9/22/2026	1.9M	$422.8M	−0.50%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	1.6M	$373.8M	−0.24%
ARIEL INVESTMENTS, LLC	8/14/2026	1.5M	$341.6M	+4.29%
PRICE T ROWE ASSOCIATES INC /MD/	8/14/2026	1.5M	$341.4M	+33.79%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	1.3M	$295.6M	+0.00%
WELLINGTON MANAGEMENT GROUP LLP	8/14/2026	1.3M	$292.2M	−20.92%
CITADEL ADVISORS LLC	9/2/2026	1.2M	$270.7M	−1.53%
BANK OF AMERICA CORP /DE/	8/14/2026	1.2M	$265.9M	+3.31%
EARNEST PARTNERS LLC	8/13/2026	1.1M	$254.0M	+15.30%
AMERIPRISE FINANCIAL INC	8/14/2026	881.2K	$199.8M	−20.57%
NEUBERGER BERMAN GROUP LLC	8/13/2026	862.7K	$195.6M	−1.34%
SEI INVESTMENTS CO	8/14/2026	813.5K	$184.5M	+7.45%
MORGAN STANLEY	8/13/2026	800.5K	$181.5M	−3.05%
CLEARBRIDGE INVESTMENTS, LLC	8/13/2026	781.3K	$177.2M	+23.50%
COOKE & BIELER LP	7/30/2026	755.6K	$171.4M	−12.94%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	8/3/2026	682.2K	$157.6M	−24.94%
VICTORY CAPITAL MANAGEMENT INC	8/7/2026	664.8K	$150.8M	−10.57%
UBS GROUP AG	8/13/2026	646.7K	$146.7M	−11.58%

Insider transactions

Insider	Type	Transacted	Price	Date
Parisotto Shannon M	S-SALE	981	$308.44	Oct 5
Parisotto Shannon M	M-EXEMPT	981	$208.44	Oct 5
Parisotto Shannon M	M-EXEMPT	981	$208.44	Oct 5

Analyst consensus

Buy37 analysts

Bearish · 0 · Hold · 10 · Bullish · 27

Earnings history

	EPS	Estimate
Q3 2024	$2.59	$2.42	Beat
Q4 2024	$2.66	$2.50	Beat
Q1 2025	$2.34	$2.06	Beat
Q2 2025	$3.12	$2.50	Beat
Q3 2025	$2.43	$2.32	Beat
Q4 2025	$2.39	$2.33	Beat
Q1 2026	$2.06	$1.96	Beat
Q2 2026	$3.02	$2.74	Beat

Peers

Company overview

IPO dateJun 23, 2000

CEOBirgit Girshick

Employees19,000

SectorHealthcare

IndustryMedical - Diagnostics & Research

CountryUS

ExchangeNew York Stock Exchange

Websitewww.criver.com

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.